306 related articles for article (PubMed ID: 26452187)
1. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
2. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
3. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
4. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
6. FLT3 Inhibitors in the Management of Acute Myeloid Leukemia.
Zappone E; Defina M; Aprile L; Bartalucci G; Gozzetti A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1028-1032. PubMed ID: 27748173
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
Ghiaur G; Levis M
Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Gebru MT; Wang HG
J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
[TBL] [Abstract][Full Text] [Related]
9. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Langdon WY
Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
[TBL] [Abstract][Full Text] [Related]
10. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Fesler MJ; Richart JM; Petruska PJ
Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
[No Abstract] [Full Text] [Related]
11. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
Grunwald MR; Levis MJ
Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
[TBL] [Abstract][Full Text] [Related]
12. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
13. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
17. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
18. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
20. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
[Next] [New Search]
